MBL-II-141

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 464691

CAS#: unknown

Description: MBL-II-141 is a BCRP inhibitor.


Chemical Structure

img
MBL-II-141
CAS# unknown

Theoretical Analysis

MedKoo Cat#: 464691
Name: MBL-II-141
CAS#: unknown
Chemical Formula: C28H23BrN2O5
Exact Mass: 546.08
Molecular Weight: 547.405
Elemental Analysis: C, 61.44; H, 4.24; Br, 14.60; N, 5.12; O, 14.61

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: MBL-II-141; MBLII-141; MBL II-141; MBL-II141; MBL-II 141; MBLII141; MBL II 141;

IUPAC/Chemical Name: 5-((4-bromobenzyl)oxy)-N-(2-(5-methoxy-1H-indol-3-yl)ethyl)-4-oxo-4H-chromene-2-carboxamide

InChi Key: YOURSKBAKQLDQW-UHFFFAOYSA-N

InChi Code: InChI=1S/C28H23BrN2O5/c1-34-20-9-10-22-21(13-20)18(15-31-22)11-12-30-28(33)26-14-23(32)27-24(3-2-4-25(27)36-26)35-16-17-5-7-19(29)8-6-17/h2-10,13-15,31H,11-12,16H2,1H3,(H,30,33)

SMILES Code: BrC(C=C1)=CC=C1COC2=C(C(C=C(C(NCCC3=CNC4=C3C=C(OC)C=C4)=O)O5)=O)C5=CC=C2

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: To be determined

Shelf Life: >2 years if stored properly

Drug Formulation: To be determined

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 547.41 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Hénin E, Honorat M, Guitton J, Di Pietro A, Payen L, Tod M. Pharmacokinetic interactions in mice between irinotecan and MBL-II-141, an ABCG2 inhibitor. Biopharm Drug Dispos. 2017 Jul;38(5):351-362. doi: 10.1002/bdd.2069. Epub 2017 Mar 23. PMID: 28207160.

2: Pires ADRA, Lecerf-Schmidt F, Guragossian N, Pazinato J, Gozzi GJ, Winter E, Valdameri G, Veale A, Boumendjel A, Di Pietro A, Pérès B. New, highly potent and non-toxic, chromone inhibitors of the human breast cancer resistance protein ABCG2. Eur J Med Chem. 2016 Oct 21;122:291-301. doi: 10.1016/j.ejmech.2016.05.053. Epub 2016 Jun 27. PMID: 27376492.

3: Payen L, Honorat M, Guitton J, Gauthier C, Bouard C, Lecerf-Schmidt F, Peres B, Terreux R, Gervot H, Rioufol C, Boumendjel A, Puisieux A, Di Pietro A. MBL- II-141, a chromone derivative, enhances irinotecan (CPT-11) anticancer efficiency in ABCG2-positive xenografts. Oncotarget. 2014 Dec 15;5(23):11957-70. doi: 10.18632/oncotarget.2566. PMID: 25474134; PMCID: PMC4323000.

4: Valdameri G, Genoux-Bastide E, Peres B, Gauthier C, Guitton J, Terreux R, Winnischofer SM, Rocha ME, Boumendjel A, Di Pietro A. Substituted chromones as highly potent nontoxic inhibitors, specific for the breast cancer resistance protein. J Med Chem. 2012 Jan 26;55(2):966-70. doi: 10.1021/jm201404w. Epub 2012 Jan 6. PMID: 22165858.